Why the study?
The coexistence of AF and CKD elevates risks of thromboembolic and hemorrhagic complications, positioning percutaneous LAAO as an alternative.
Does percutaneous left atrial appendage occlusion reduce thromboembolic events and major bleeding in patients with non-valvular atrial fibrillation and chronic kidney disease compared to oral anticoagulant therapy?
Does percutaneous left atrial appendage occlusion reduce thromboembolic events and major bleeding in patients with non-valvular atrial fibrillation and chronic kidney disease compared to oral anticoagulant therapy?
Answers are grounded in this paper and cite their sources.
LAAO provides a significant reduction in thromboembolic events and major bleeding complications in patients with non-valvular AF and CKD compared to oral anticoagulation.
Introduction: The coexistence of atrial fibrillation (AF) and chronic kidney disease (CKD) increases the risk of thromboembolic complications, as well as hemorrhagic incidents - percutaneous left atrial appendage occlusion (LAAO) is an alternative. Aim: To evaluate the long-term outcomes of LAAO performed in patients with CKD and non-valvular AF. Material and methods: ). The mean follow-up period was 25.56 months. Conclusions: Considering the significant reduction in thromboembolic events, with a simultaneous reduction of major bleeding complications, LAAO is a safe and effective alternative for AF patients with CKD.
No takes yet. Share an insight, caveat, or question.
Michlicka-Kłyś et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: